Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Authors:
Open Access
- 21 October 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (2) , 215-227
Abstract
Background: The ALLEGRO phase IIa and IIb/III (NCT02974868 and NCT03732807) studies have demonstrated that ritlecitinib is effective and well tolerated in adults and adolescents with alopecia areata (AA) up to 48 weeks. Objectives: To assess the efficacy of ritlecitinib through month 24 and safety through data cutoff in the ALLEGRO phase IIb/III study and the ongoing long-term open-label phase III ALLEGRO-LT study (NCT04006457). Methods: Patients aged ≥ 12 years with AA and ≥ 50% scalp hair loss from ALLEGRO IIb/III who rolled over to ALLEGRO-LT after up to 48 weeks were included. Proportions of patients with responses based on clinician-reported Severity of Alopecia Tool (SALT) scores of ≤ 20 and ≤ 10, eyebrow assessment (EBA) and eyelash assessment (ELA), patient global impression of change (PGI-C) and patient satisfaction with hair growth were reported through month 24 for patients who received ritlecitinib 50 mg daily with or without a 200-mg 4-week daily loading dose. Observed and imputed data [last observation carried forward (LOCF)] were reported up to 9 December 2022. Safety was assessed throughout. Results: At month 12, a SALT score ≤ 20 was achieved by 45.1% and 45.9% (observed) and 40.3% and 41.8% (LOCF) of the 191 and 194 patients who received ritlecitinib 50 mg and ritlecitinib 200 mg/50 mg, respectively. At month 24, these proportions increased to 60.8% and 63.1% (observed) and 46.1% and 50.8% (LOCF), respectively. Patients with abnormal EBA or ELA scores at baseline achieved responses at month 24 [EBA observed: 57.6% (50 mg), 61.0% (200/50 mg); EBA LOCF: 46.8% (50 mg), 50.9% (200/50 mg); ELA observed: 51.2% (50 mg), 62.7% (200/50 mg); ELA LOCF: 43.2% (50 mg), 51.7% (200/50 mg)]. PGI-C response was achieved by patients at month 24 [observed: 70.0% (50 mg), 76.4% (200/50 mg); LOCF: 56.6% (50 mg), 65.5% (200/50 mg)]. Safety profiles for both treatment groups were consistent with the known safety profile of ritlecitinib. Conclusions: Ritlecitinib has clinically meaningful and sustained efficacy beyond 1 year with a favourable safety and tolerability profile, supporting its long-term use in patients aged ≥ 12 years with AA. GraphicalKeywords
Funding Information
- Pfizer Inc
This publication has 22 references indexed in Scilit:
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramAmerican Journal of Clinical Dermatology, 2024
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative ReviewDermatology and Therapy, 2023
- Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured PopulationJAMA Dermatology, 2023
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)American Journal of Clinical Dermatology, 2023
- Treatment Patterns and Treatment Satisfaction Among Adults with Alopecia Areata in the United StatesAdvances in Therapy, 2022
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkersJournal of Allergy and Clinical Immunology, 2022
- Development of the alopecia areata scale for clinical use: Results of an academic–industry collaborative effortJournal of the American Academy of Dermatology, 2022
- Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysisJournal of the American Academy of Dermatology, 2020
- The autoimmune basis of alopecia areata: A comprehensive reviewAutoimmunity Reviews, 2015
- Alopecia areata: A long term follow-up study of 191 patientsJournal of the American Academy of Dermatology, 2006